Data Presentation: Topline Results from Year One of the CARDINAL Study of Bardoxolone Methyl in Alport Syndrome

Phase 3 Year 1 portion of the CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome met its primary and key secondary endpoints. 

  • After 48 weeks of treatment, patients treated with bardoxolone methyl had a statistically significant improvement compared to placebo in mean estimated glomerular filtration rate (eGFR).
  • After 48 weeks of treatment and a four-week withdrawal period, patients treated with bardoxolone methyl had a statistically significant improvement compared to placebo in mean off-treatment eGFR.
  • Bardoxolone methyl treatment was generally reported to be well-tolerated and showed a similar safety profile to the Phase 2 portion of the CARDINAL study.